Jamaican scientist Dr Henry Lowe has received an exclusive patent from the United States of America (USA) for the use of Caflanone to treat pancreatic cancer.
Through his USA-based company, Flavocure LLC, Lowe, the executive chairman and his team of scientists developed Caflanone from the cannabis-based flavonoid, from a rare strain of the plant that is found in Jamaica.
“This particular plant has a relatively high concentration of flavonoids peculiar to cannabis. The drug was subsequently synthesised through proprietary methodology and is now available in commercial quantities for clinical trials,” Flavocure said in a release.
According to Lowe, Caflanone’s research will continue, with Harvard Medical School forming a partnership with Flavocure, for the clinical trials.
Harvard will use patented modern technology to deliver Caflanone directly to cancer tissues that will result in fewer side effects that most drugs create.